Public Release:  Worm infections in developing countries: Veterinary drugs improve the health of school children

Swiss Tropical and Public Health Institute

IMAGE

IMAGE: School children are investigated for worm infection. view more

Credit: Benjamin Speich / Swiss TPH

This news release is available in German.

Hookworms and whipworms are detrimental to health. Children in many developing countries in particular are prone to regular infection via contaminated soil due to a lack of latrines and clean water. Whipworm eggs enter the body via the gastrointestinal tract and evolve over several devel-opment stages. To contain the health risks of worm infections, the WHO recommends annual de-worm treatment for children and at-risk groups (such as field hands and miners). However, the recommended standard treatment appears to have little effect against the widespread whipworm (Trichuris trichiura).

"We remembered that there was an effective deworming drug used in veterinary medicine," says head of the study Jennifer Keiser, from the Swiss Tropical and Public Health Institute. Following a preliminary study in the laboratory, her group tested the veterinary treatment 'Oxantel Pamoate' in combination with the standard treatment, Albendazole. The randomised double-blind trial with school children with worm infections took place on the East African island of Pemba (Tanzania). After one treatment with this combination therapy, 31% of the children were free of worm infec-tions. The number of worm eggs in the children's stools decreased by 96% after one treatment.

Veterinary medicine for neglected worm infections

'Oxantel Pamoate' was developed in the 1970s to combat whipworm. Today, it is widely used in veterinary deworming drugs in combination with other substances. Studies in the 1970s showed that 'Oxantel Pamoate' is also a safe and effective way of tackling whipworm infections in humans. Yet, the drug was soon forgotten about and was never widely used for humans.

"Health experts in the field of worm infections have been discussing its use for some years now," says Jennifer Keiser: "The problem was the availability of the active ingredient as a single sub-stance." The veterinary medicine manufacturers did not want to release the drug for human clini-cal trials and the drug is not commercially available.

Successful collaboration with pharmacists at the University of Basel

The solution was found during a collaboration with pharmacists at the University of Basel. Jörg Huwyler's laboratory in the Centre for Pharmaceutical Sciences succeeded in producing a tablet whose taste and colour were attractive to children. Thanks to this expertise, it was possible to de-velop the substance entirely independently of the pharmaceutical industry. Drug doses and delivery are currently being improved in further clinical trials. On the strength of the study, the WHO could extend its recommendation to include this substance in future. This would improve the health of millions of children worldwide.

###

The study was financed by the Swiss National Science Foundation (SNSF) and the Medicor Foun-dation.

Study

Oxantel Pamoate-Albendazole for Trichuris trichiura Infection. B. Speich, SM. Ame, SM. Ali, R. Alles, J. Huwyler, J. Hattendorf, J. Utzinger, M. Albonico , and J. Keiser, Ph.D. N Engl J Med 770;7, p. 610ff.

Contacts

Professor Jennifer Keiser, Swiss Tropical and Public Health Institute
jennifer.keiser@unibas.ch, Tel +41 61 284 82 18

Benjamin Speich, Swiss Tropical and Public Health Institute
benjamin.speich@unibas.ch, Tel +41 61 284 82 86

Dr. Christian Heuss, Communication, Swiss Tropical and Public Health Institute
christian.heuss@unibas.ch, Tel +41 61 284 86 83

About the Swiss Tropical and Public Health Institute (Swiss TPH)

The Swiss Tropical and Public Health Institute (Swiss TPH) is one of Switzerland's leading public and global health institutions. Associated with the University of Basel, the Institute combines re-search, teaching and service provision at local, national and international level. The Swiss TPH is a public sector organisation and receives around 17% of its budget of approximately 80 million francs from core contributions from the cantons of Basel-Stadt and Basel-Landschaft (10%) and from the federal government (8%). The remainder (82%) is acquired by competing for funds. The Institute has more than 600 employees working in 20 countries. Professor Marcel Tanner is head of the Institute.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.